4.8 Article

Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 118, 期 3, 页码 924-934

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI34013

关键词

-

向作者/读者索取更多资源

The proliferation and differentiation of hematopoietic stem cells (HSCs) is finely regulated by extrinsic and intrinsic factors via various signaling pathways. Here we have shown that, similar to mice deficient in the lipid phosphatase SHIP, loss of 2 Src family kinases, Lyn and Hck, profoundly affects HSC differentiation, producing hematopoietic progenitors with increased proliferation, reduced apoptosis, growth factor-independent survival, and skewed differentiation toward M2 macrophages. This phenotype culminates in a Stat5-dependent myeloproliferative disease that is accompanied by M2 macrophage infiltration of the lung. Expression of a membrane-bound form of SHIP in HSCs lacking both Lyn and Hck restored normal hematopoiesis and prevented myeloproliferation. In vitro and in vivo studies suggested the involvement of autocrine and/or paracrine production of IL-3 and GM-CSF in the increased proliferation and myeloid differentiation of HSCs. Thus, this study has defined a myeloproliferative transformation-sensitive signaling pathway, composed of Lyn/Hck, SHIP, autocrine/paracrine cytokines, and Stat5, that regulates HSC differentiation and M2 macrophage programming.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Microbiology

False-Positive Results for Human Immunodeficiency Virus Type 1 Nucleic Acid Amplification Testing in Chimeric Antigen Receptor T Cell Therapy

Jocelyn R. Hauser, Hong Hong, N. Esther Babady, Genovefa A. Papanicolaou, Yi-Wei Tang

JOURNAL OF CLINICAL MICROBIOLOGY (2020)

Article Oncology

PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN

Friederike Pastore, Neha Bhagwat, Alessandro Pastore, Aliaksandra Radzisheuskaya, Abdul Karzai, Aishwarya Krishnan, Bing Li, Robert L. Bowman, Wenbin Xiao, Aaron D. Viny, Anouar Zouak, Young C. Park, Keith B. Cordner, Stephanie Braunstein, Jesper L. Maag, Alexander Grego, Jaanvi Mehta, Min Wang, Hong Lin, Benjamin H. Durham, Richard P. Koche, Raajit K. Rampal, Kristian Helin, Peggy Scherle, Kris Vaddi, Ross L. Levine

CANCER DISCOVERY (2020)

Article Hematology

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia

Wenbin Xiao, Alexander Chan, Michael R. Waarts, Tanmay Mishra, Ying Liu, Sheng F. Cai, Jinjuan Yao, Qi Gao, Robert L. Bowman, Richard P. Koche, Isabelle S. Csete, Nicole L. DelGaudio, Andriy Derkach, Jeeyeon Baik, Sophia Yanis, Christopher A. Famulare, Minal Patel, Maria E. Arcila, Maximilian Stahl, Raajit K. Rampal, Martin S. Tallman, Yanming Zhang, Ahmet Dogan, Aaron D. Goldberg, Mikhail Roshal, Ross L. Levine

Summary: Plasmacytoid dendritic cell expansion in acute myeloid leukemia is poorly studied, and pDC-AML patients often have adverse risk stratification with RUNX1 mutations. CD123 targeting represents a potential treatment approach for pDC-AML.
Article Hematology

A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN

Wenbin Xiao, Linde A. Miles, Robert L. Bowman, Vidushi Durani, Helen S. Tian, Nicole L. DelGaudio, Tanmay Mishra, Menglei Zhu, Yanming Zhang, Sarah E. Stump, Martin S. Tallman, Ross L. Levine, Sheng F. Cai

BLOOD ADVANCES (2020)

Article Hematology

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Maximilian Stahl, Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao, Jacob Glass, Amber C. King, Anthony F. Daniyan, Christopher Famulare, Bernadette M. Cuello, Troy Z. Horvat, Omar Abdel-Wahab, Ross L. Levine, Aaron D. Viny, Eytan M. Stein, Sheng F. Cai, Mikhail Roshal, Martin S. Tallman, Aaron D. Goldberg

Summary: Combination therapy of venetoclax is effective in many patients with relapsed or refractory AML, with azacitidine+venetoclax showing higher response rates compared to low-dose cytarabine+venetoclax. Clinical and molecular characteristics of patients may predict treatment outcomes in this population.

BLOOD ADVANCES (2021)

Article Hematology

ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML

Barbara Spitzer, Filemon S. Dela Cruz, Glorymar D. Ibanez Sanchez, Yanming Zhang, Wenbin Xiao, Ryma Benayed, Alina Markova, M. Irene Rodriguez-Sanchez, Nancy Bouvier, Mikhail Roshal, Andrew L. Kung, Neerav Shukla

Summary: MLN-Eo is a WHO-established category of hematologic malignancies, and we report a case of an 8-month-old infant diagnosed with ETV6-FLT3 driven MLN-Eo who achieved complete remission after treatment. This case highlights the clinical utility of ex vivo drug testing in targeted therapies.

BLOOD ADVANCES (2021)

Article Hematology

BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation

Bing Li, Wenbin An, Hua Wang, Timour Baslan, Shoron Mowla, Aishwarya Krishnan, Wenbin Xiao, Richard P. Koche, Ying Liu, Sheng F. Cai, Zhijian Xiao, Andriy Derkach, Ilaria Iacobucci, Charles G. Mullighan, Kristian Helin, Scott W. Lowe, Ross L. Levine, Raajit K. Rampal

Summary: Leukemic transformation (LT) of myeloproliferative neoplasm (MPN) is often fatal, with TP53 mutational inactivation being the most common event. This study demonstrates that biallelic inactivation of Trp53 leads to LT, specifically a pure erythroleukemia (PEL), arising from the megakaryocyte-erythroid progenitor population. Activation of the bone morphogenetic protein 2/SMAD pathway contributes to abnormal self-renewal of megakaryocyte-erythroid progenitors during LT. The Jak2/Trp53 mutant PEL is characterized by recurrent copy number alterations and DNA damage, and combination WEE1 and poly(ADP-ribose) polymerase inhibition shows potential as a therapeutic strategy.
Review Pathology

Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop

Magdalena Czader, Catalina Amador, James R. Cook, Devang Thakkar, Clay Parker, Sandeep S. Dave, Ahmet Dogan, Amy S. Duffield, Reza Nejati, German Ott, Wenbin Xiao, Mariusz Wasik, John R. Goodlad

Summary: This article discusses the progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and B-cell prolymphocytic leukemia (B-PLL). The study highlights the complexity and diagnostic challenges of these diseases, as well as the importance of molecular genetic studies in diagnosis and treatment.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2023)

Review Pathology

Phenotypic and genotypic infidelity in B-lineage neoplasms, including transdifferentiation following targeted therapy: Report from the 2021 SH/EAHP Workshop

John R. Goodlad, Wenbin Xiao, Catalina Amador, James R. Cook, Lanie Happ, Devang Thakkar, Sandeep Dave, Ahmet Dogan, Amy Duffield, Reza Nejati, German Ott, Mariusz Wasik, Magdalena Czader

Summary: Session 2 of the 2021 Society for Hematopathology and European Association for Haematopathology Workshop presented examples of lineage infidelity and transdifferentiation in B-lineage neoplasms, including after targeted therapy. A total of 20 cases were examined, with whole-exome sequencing and genome-wide RNA expression analysis conducted on a subset. The findings demonstrated lineage switch to acute myeloid leukemia or mixed-phenotype acute leukemia in multiple cases of B-cell acute lymphoblastic leukemia (B-ALL) upon relapse, as well as changes in maturational state without lineage switch. Aberrant T-cell antigen expression was also observed in mature B-cell lymphoma cases, with correlations to alterations in tumor cell gene expression patterns.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2023)

Review Pathology

Progression of Hodgkin lymphoma and plasma cell neoplasms: Report from the 2021 SH/EAHP Workshop

Reza Nejati, Catalina Amador, Magdalena Czader, Elizabeth Thacker, Devang Thakkar, Sandeep S. Dave, Ahmet Dogan, Amy Duffield, John R. Goodlad, German Ott, Mariusz A. Wasik, Wenbin Xiao, James R. Cook

Summary: The 2021 Society for Hematopathology/European Association for Haematopathology Workshop summarized cases of progression in Hodgkin lymphoma, plasmablastic myeloma, and plasma cell myeloma. Whole-exome sequencing and whole-genome RNA expression analysis were performed on selected cases, providing valuable insights into the molecular characterization and progression mechanisms of these neoplasms and potential therapeutic targets.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2023)

Review Pathology

Progression of follicular lymphoma and related entities: Report from the 2021 SH/EAHP Workshop

Amy S. Duffield, Ahmet Dogan, Catalina Amador, James R. Cook, Magdalena Czader, John R. Goodlad, Reza Nejati, Wenbin Xiao, Lanie Happ, Clay Parker, Elizabeth Thacker, Devang Thakkar, Sandeep S. Dave, Mariusz A. Wasik, German Ott

Summary: The 2021 Society for Hematopathology and European Association for Haematopathology Workshop focused on the molecular and cytogenetic mechanisms of transformation and transdifferentiation in lymphoid neoplasms. Gene alteration analysis and expression profiling were performed on 45 cases, revealing distinct categories of transformation in diffuse large B-cell lymphoma/high-grade B-cell lymphoma with rearrangements of MYC and BCL2. Cytogenetic abnormalities, such as MYC and NOTCH1 rearrangements, as well as single gene alterations, including TP53, were identified as important factors in transformation.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2023)

Review Pathology

Transformations of marginal zone lymphomas and lymphoplasmacytic lymphomas: Report from the 2021 SH/EAHP Workshop

James R. Cook, Catalina Amador, Magdalena Czader, Amy Duffield, John Goodlad, German Ott, Wenbin Xiao, Sandeep Dave, Devang Thakkar, Elizabeth Thacker, Ahmet Dogan, Mariusz Wasik, Reza Nejati

Summary: The conclusions of the 2021 Society for Hematopathology/European Association for Haematopathology workshop on transformations of marginal zone lymphoma (MZL) and lymphoplasmacytic lymphoma (LPL) were summarized. The most common transformation is to diffuse large B-cell lymphoma (DLBCL), but there are also other transformation events to different types of lymphomas. Comprehensive analysis, including sequencing studies, can aid in the diagnosis and classification of these rare cases.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2023)

Review Pathology

Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop

Catalina Amador, James R. Cook, Magdalena Czader, Amy Duffield, John Goodlad, Reza Nejati, German Ott, Wenbin Xiao, Sandeep Dave, Mariusz A. Wasik, Ahmet Dogan

Summary: Objectives of sessions 8 and 9 were to study examples of transdifferentiation, lineage infidelity, and progression in T/NK-cell neoplasms. A total of 28 cases were analyzed, with a subset undergoing whole-exome sequencing and genome-wide RNA expression analysis. Transdifferentiation to mature myeloid neoplasms, phenotypic infidelity in mature T-cell lymphomas, and disease progression in T-cell lymphoproliferative disorders were observed. This cohort of cases provides insights into current concepts of transdifferentiation and progression in T/NK-cell neoplasms.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2023)

Editorial Material Hematology

Primary thymic marginal zone lymphoma with amyloidosis

Krasimira A. Rozenova, Wenbin Xiao

Letter Oncology

Hairy cell leukemia expresses programmed death-1

Priyadarshini Kumar, Qi Gao, Alexander Chan, Natasha Lewis, Allison Sigler, Janine Pichardo, Wenbin Xiao, Mikhail Roshal, Ahmet Dogan

BLOOD CANCER JOURNAL (2020)

暂无数据